Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2018 1
2020 1
2021 1
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yinhuan li (41 results)?
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study.
Li Y, Qi L, Wang Y, Zhao X, Lv S, Feng Y, Liu C, Li P, Xiong B, Guo Y, Lv D, Liu Y, Mao T, Yuan K, Cheng X, Li Y, Wang X. Li Y, et al. Anticancer Drugs. 2023 Jul 1;34(6):763-774. doi: 10.1097/CAD.0000000000001456. Epub 2022 Nov 19. Anticancer Drugs. 2023. PMID: 36730296 Clinical Trial.
Bioequivalence and safety evaluation of two preparations of metformin hydrochloride sustained-release tablets (Boke® and Glucophage®-XR) in healthy Chinese volunteers: a randomized phase I clinical trial.
Sun ML, Liu C, Bai HH, Wei YL, Zhang W, Liu HJ, Li YJ, Liu L, Wang Y, Tong YX, Gao Q, Liu QY, Wang X. Sun ML, et al. Ann Med. 2022 Dec;54(1):2626-2635. doi: 10.1080/07853890.2022.2125574. Ann Med. 2022. PMID: 36135935 Free PMC article. Clinical Trial.
A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx ® in advanced breast cancer.
Li Y, Qi L, Wang Y, Li Y, Lei C, Zhang Y, Cheng X, Liu J, Bai H, Zhao X, Lv S, Xiong B, Liu J, Shi Y, Zhou H, Li H, Liu L, Jiang H, Ouyang W, Li X, Li Y, Wang X. Li Y, et al. Front Oncol. 2022 Dec 20;12:1070001. doi: 10.3389/fonc.2022.1070001. eCollection 2022. Front Oncol. 2022. PMID: 36605440 Free PMC article.
Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
Liu L, Qi L, Lei C, Wang Y, Zhang W, Liu Y, Li P, Bai H, Li Y, Li Y, Liu J, Xie L, Wang X. Liu L, et al. Among authors: li y. Int Immunopharmacol. 2022 May;106:108599. doi: 10.1016/j.intimp.2022.108599. Epub 2022 Feb 19. Int Immunopharmacol. 2022. PMID: 35193054 Clinical Trial.
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study.
Li Y, Qi L, Bai H, Sun C, Xu S, Wang Y, Han C, Li Y, Liu L, Cheng X, Liu J, Lei C, Tong Y, Sun M, Yan L, Chen W, Liu X, Liu Q, Xie L, Wang X. Li Y, et al. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0106321. doi: 10.1128/AAC.01063-21. Epub 2021 Sep 7. Antimicrob Agents Chemother. 2021. PMID: 34491805 Free PMC article. Clinical Trial.